Kidney Protection: Can Lotensin Offer Hope for Chronic Renal Failure?
"New research explores how Lotensin might combat advanced kidney disease by targeting key factors in renal fibrosis."
Chronic kidney disease (CKD), a significant global health challenge, arises from various mechanisms leading to the accelerated proliferation of cells, excessive matrix deposition and eventual kidney failure. Exploring effective therapeutic interventions is crucial to alleviate the burden on affected individuals and healthcare systems.
Transforming growth factor-β1 (TGF-β1) is a potent stimulator of mesangial cell proliferation and a key player in fibrogenesis. Alpha-smooth muscle actin (α-SMA) serves as a marker for cells, with elevated expression in kidneys signaling myofibroblast transformation and extracellular matrix deposition. Understanding the dynamics of these factors is essential for developing targeted therapies.
This article dives into recent research investigating the protective role of Lotensin, an angiotensin-converting enzyme (ACE) inhibitor, in advanced chronic renal failure. The study explores Lotensin's impact on TGF-β1 and α-SMA expression in a rat model, revealing potential mechanisms for slowing disease progression.
CKD Burden and Monitoring
The CDC's national estimates, updated in March 2026, describe chronic kidney disease as a condition that may lead to high blood pressure, heart disease, stroke, and early death. The CDC also states that people with CKD, and those at risk, can take steps to protect their kidneys with help from health care providers. The United States Renal Data System collects, analyzes, and distributes information about CKD and end-stage renal disease in the United States.
From Definition to Experimental Protection
Chronic kidney disease was redefined in the new millennium as an alteration in kidney morphology, function, blood, or urine composition lasting at least three months. This broad definition can include conditions such as kidney scarring after acute pyelonephritis or having a single kidney. Research on Lotensin later examined advanced chronic kidney disease in rats with 5/6 nephrectomy and reported protection associated with downregulation of TGF-β1 and α-SMA, factors involved in renal fibrosis.
How Does Lotensin Protect Failing Kidneys?
Researchers investigated Lotensin's effects on advanced chronic kidney disease using a rat model mimicking 5/6 nephrectomy (5/6 Nx). This model replicates the reduced nephron count and functional abnormalities seen in CKD. Rats were divided into three groups: a sham group, a 5/6 Nx group, and a Lotensin group (receiving oral Lotensin for nine weeks after 5/6 Nx).
- Reduced Kidney Damage: Lotensin significantly reduced the 5/6 Nx-induced elevation in blood urea nitrogen, serum creatinine, and 24-h urinary protein excretion (UPE) rates.
- Improved Blood Parameters: Lotensin increased red blood cell count, plasma albumin, and hemoglobin levels, counteracting the effects of 5/6 Nx.
- Renal Morphology: Lotensin improved overall kidney structure.
- Downregulation of TGF-β1 and α-SMA: Lotensin dramatically downregulated the renal expression of TGF-β1 and α-SMA induced by 5/6 Nx.
Fibrosis Pathways Under Study
Recent research describes chronic renal failure as involving glomerular atrophy and fibrosis, along with renal tubular hypertrophy, necrosis, and occlusion that can lead to glomerular sclerosis and interstitial fibrosis. Other work reports that increased TGF-β1 and α-SMA are associated with chronic renal failure risk. Studies of exosomes derived from bone-marrow mesenchymal stem cells have also targeted fibrosis and apoptosis, although the cited study notes that exosomes had not been used for fibrosis associated with CKD during menopause.
Evidence Limits in Advanced Disease
The cited rat study reports that Lotensin generally reversed adverse effects of 5/6 nephrectomy on renal function, suggesting a protective effect in that model. However, the same research emphasizes that Lotensin's role in the intermediate and late stages of chronic renal failure had remained largely unknown before the investigation. The evidence therefore supports an experimental protective signal, not a definitive conclusion about treatment of advanced human disease.
Finerenone Compared with Spironolactone
A real-world cohort study emulating a randomized clinical trial found that finerenone was associated with lower risks of all-cause mortality, cardiovascular events, and kidney events than spironolactone in people with CKD and type 2 diabetes. A separate post hoc analysis in patients with treatment-resistant hypertension and CKD associated finerenone with a lower risk of hyperkalemia and treatment discontinuation than spironolactone, although its systolic blood-pressure reduction was lower. These findings describe comparative associations and do not directly establish that finerenone is superior to Lotensin.
What Does This Mean for Kidney Disease Treatment?
This research suggests that Lotensin could play a protective role in advanced chronic renal failure by modulating TGF-β1 and α-SMA expression. These findings offer insights into new applications of existing agents for kidney disease.
Precision Tools and Global Action
The Lancet describes CKD as receiving renewed attention following adoption of the WHO resolution on kidney health in November 2025, while warning that implementation can face opposition, inertia, and indifference. A 2023 review reports that CKD affects over 850 million people globally and highlights new biomarkers, imaging methods, artificial intelligence, and other tools for more precise diagnosis and management. Future progress therefore depends on both scientific innovation and effective implementation of global kidney-health commitments.
CKD as a Multisystem Challenge
A 2026 Lancet Series describes CKD as a complex, multisystem condition that rarely occurs in isolation. It outlines therapeutic advances aimed at shared inflammatory, metabolic, and fibrotic pathways across CKD, cardiovascular disease, diabetes, obesity, and infection. The series identifies novel therapeutics, including SGLT2 inhibitors and non-steroidal therapies, within this broader treatment landscape.
Global Access and Quality of Life
The NCT06058585 study description states that CKD affects over 800 million people globally and is projected to be the fifth most common cause of death by 2040. It also reports that CKD can progress to kidney failure, increase the risk of early death and heart disease, and lead to poorer quality of life. These consequences help explain why chronic kidney disease care is a major human and health-system concern.
While Lotensin has been used to reduce urinary protein excretion and improve renal function in early-stage chronic renal failure, its effectiveness in later stages has been debated. This study provides evidence for its potential benefits in advanced stages, warranting further clinical validation.
Further research is needed to fully elucidate the mechanisms by which Lotensin regulates TGF-β1 and α-SMA, and to confirm these findings in human clinical trials. The insights gained could pave the way for new therapeutic strategies to combat chronic renal failure.